Clinical trials: Cellular Rejection
Kidney Transplant Rejection, Positive FCXM (T or B Cell Positive)
Spleen Transplant in Solid Organ Transplantation
Although the notions that kidney transplantation is the treatment of choice for patients with end-stage renal disease and that simultaneous kidney and pancreas transplant is the only treatment able to restore euglycemia in…
- Conditions
- Kidney Transplant Rejection, Positive FCXM (T or B Cell Positive), Positive CDC Cross-Match (B Cell Positive), Kidney/Pancreas Transplant Rejection
- Trial name
- NCT04827186
- Testing
- Spleen Transplantation/Removal
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Renal Transplant Rejection, Fibrosis
Mesenchymal Stromal Cell Therapy in Renal Recipients
This study will test the hypothesis that MSCs in combination with Everolimus facilitate Tacrolimus withdrawal, reduce fibrosis and decrease the incidence of opportunistic infections compared to standard tacrolimus dose.
- Trial name
- MSCs (NCT02057965)
- Testing
- Mesenchymal Stromal Cells
- Where
- Netherlands
- Volunteers
- 70 people
- Sponsor
- Leiden University Medical Center
Acute Cellular Graft Rejection, Cardiac Sarcoidosis
[68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation
Acute myocardial inflammation is an heterogenic syndrome involving different clinical pathologies with different outcome. For the purpose of this study protocol, we focuse on three entities of this syndrome, namely the acute…
- Conditions
- Acute Cellular Graft Rejection, Cardiac Sarcoidosis, Myocarditis Due to Drug
- Trial name
- NCT05499637
- Testing
- [68Ga]Ga-PentixaFor PET/CT
- Where
- Switzerland
- Volunteers
- 25 people
- Sponsor
- John O. Prior
Transplant;Failure,Kidney, Transplant; Failure, Pancreas
Eliminating the Need for Pancreas Biopsy Using Peripheral Blood Cell-free DNA
Donor-derived cell-free DNA (dd-cfDNA) has shown promise as an early marker for cellular injury caused by rejection. dd-cfDNA changes may also indicate other injuries that lead to progressive decline in transplant organ function…
- Conditions
- Transplant;Failure,Kidney, Transplant; Failure, Pancreas, Rejection Acute Renal, Rejection Acute Pancreas
- Trial name
- PancDX (NCT04166149)
- Testing
- dd-cfDNA Blood Test
- Where
- 3 sites in United States
- Volunteers
- 140 people
- Sponsor
- University of Maryland, Baltimore
Kidney Transplant Failure and Rejection
BIOtechnology Applied to Renal TRansplantation With IMmunobiogram
Immunobiogram (IMBG) is a novel in vitro diagnostic bioassay developed by Biohope Scientific Solutions for Human Health SL, that allows to measure the pharmacodynamic response to individual immunosuppressive drugs in patients…
- Trial name
- BIOTRAIM (NCT05816486)
- Testing
- Immunobiogram
- Where
- 15 sites in Brazil, France and 3 more
- Volunteers
- 443 people
- Sponsor
- Biohope Scientific Solutions for Human Health, S.L.
End-stage Renal Failure, Kidney Graft Rejection
Reference Group Trial for The ONE Study
To investigate the progression of the immunological response in living-donor kidney transplant recipients treated with a standard immunosuppressive regimen.
- Trial name
- NCT01656135
- Testing
- Blood drawing for immune monitoring and questionnaires
- Where
- 8 sites in United States, France and 3 more
- Volunteers
- 70 people
- Sponsor
- University of Regensburg
Solid Organ Transplant Complications, Solid Organ Transplant Recipients
Phase I Trial on the Safety of Delayed Infusion of a Naïve T Cell-Depleted Hematopoietic Graft With Memory T Cells in Solid Organ Transplant Recipients
The goal of this clinical trial is to evaluate the safety and feasibility of inducing hematopoietic mixed chimerism to promote immune tolerance and potentially reduce the need for lifelong immunosuppression in pediatric and adult…
- Conditions
- Solid Organ Transplant Complications, Solid Organ Transplant Recipients, Solid Organ Transplant Rejection
- Trial name
- DUALGRAFT (NCT06997471)
- Testing
- Investigational cellular therapy consisting on a HSCT using a graft enriched in CD34+, depleted of naïve T-lymphocytes and supplemented with memory lymphocytes
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Francisco Hernández Oliveros
Hematologic Malignancy, Bone Marrow Transplant Rejection
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor…
- Conditions
- Hematologic Malignancy, Bone Marrow Transplant Rejection, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
- Trial name
- NCT06398457
- Testing
- Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Kidney Transplant Rejection
Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA
Kidney transplant rejection remains a significant challenge to long-term graft survival. While histological biopsy continues to be the gold standard for diagnosing rejection, noninvasive biomarkers such as donor-derived cell-free…
- Trial name
- NCT07415876
- Testing
- Retrospective Cohort Enrollment, Prospective Cohort Enrollment
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Virginia Commonwealth University
Antibody-Mediated Graft Rejection
Cell-based Assays for Antibody-mediated Transplant Rejection
Goal: The goal of this study is to validate blood tests, which can detect antibody-mediated rejection (ABMR) after renal transplantation.
- Trial name
- NCT03916822
- Testing
- Alloantigen-specific B-cells
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Plexision
Heart Transplant Rejection
Donor-derived Cell Free DNA as a New Biomarker in Cardiac Acute Rejection
FreeDNA-CAR is a prospective, observational multicenter study, that will include a total of 200 adult heart transplant (HT) patients from 14 centers in Spain.
- Trial name
- FreeDNA-CAR (NCT04973943)
- Testing
- Donor-derived cell Free DNA
- Where
- 12 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Puerta de Hierro University Hospital
Kidney Transplant Rejection, Kidney Transplant Infection
Dynamic Changes of Torquetenovirus (TTV) Load in Chinese Renal Transplant Recipients
The goal of this observational study is to learn about dynamic changes of Torquetenovirus (TTV) load in Chinese renal transplant recipients.
- Conditions
- Kidney Transplant Rejection, Kidney Transplant Infection, Virus, Immunosuppression
- Trial name
- TTV (NCT05727709)
- Where
- 5 sites in China
- Volunteers
- 220 people
- Sponsor
- Tongji Hospital
Liver Dysfunction, Rejection, Transplant
Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection
This study involves the use of a drug called Thymoglobulin, which is approved in the US to treat kidney transplant rejection and in Canada to treat and prevent kidney transplant rejection.
- Conditions
- Liver Dysfunction, Rejection, Transplant, Transplantation, Liver
- Trial name
- NCT00117689
- Testing
- Thymoglobulin, Corticosteroid, Tacrolimus
- Where
- 16 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- Genzyme, a Sanofi Company
Heart Transplantation
Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Prevent Rejection in Heart Transplant Children
The investigators developed a protocol to isolate Treg cells from thymic tissue (thyTreg) discarded in pediatric cardiac surgeries.
- Trial name
- THYTECH (NCT04924491)
- Testing
- Autologous thyTreg
- Where
- Spain
- Volunteers
- 11 people
- Sponsor
- Rafael Correa-Rocha
Evidence of Liver Transplantation
Human Mesenchymal Stem Cells Induce Liver Transplant Tolerance
Liver transplantation is the only lifesaving intervention for patients with end-stage liver diseases. Despite the ability of current immunosuppressive agents to reduce the incidence of acute rejection, the rate of acute rejection…
- Trial name
- NCT01690247
- Testing
- Conventional plus UC-MSC
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Beijing 302 Hospital
Acute Rejection
Efficacy of Rituximab in Acute Cellular Rejection in Renal Transplant Patients
Acute kidney allograft rejection is the major cause for a loss of graft function and has a negative impact on long-term graft survival.
- Trial name
- RIACT (NCT01117662)
- Testing
- Rituximab
- Where
- 14 sites in Germany
- Volunteers
- 13 people
- Sponsor
- Hannover Medical School
Transplanted Organ Rejection
A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation
A randomized controlled study to evaluate the safety, efficacy, and overall benefit of FCR001 cell therapy in de novo living donor renal transplantation.
- Trial name
- FREEDOM-1 (NCT03995901)
- Testing
- FCR001
- Where
- 18 sites in United States
- Volunteers
- 15 people
- Sponsor
- Talaris Therapeutics Inc.
Kidney Transplant Recipients
Non Invasive Blood Test To Diagnose Acute Rejection After Kidney Transplantation
This is a prospective, multicenter, observational study of kidney transplant subjects where blood specimens, intended for dd-cfDNA and other future research purposes, will be drawn after transplant
- Trial name
- DART (NCT02424227)
- Where
- 14 sites in United States
- Volunteers
- 401 people
- Sponsor
- CareDx
Kidney Transplantation, Renal Transplantation
Tolerance by Engaging Antigen During Cellular Homeostasis
Anti-rejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent rejection of the new organ.
- Conditions
- Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient
- Trial name
- TEACH (NCT03504241)
- Testing
- Donor-derived Mesenchymal Stromal Cells, alemtuzumab, belatacept
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplantation, Acute Rejection of Renal Transplant
Donor-derived Cell-free DNA in Kidney Transplant Recipients
Donor-derived cell-free DNA (dd-cfDNA) is a promising non-invasive biomarker of kidney allograft rejection. In this prospective, single center, observational monitoring study, we aim to evaluate a role of dd-cfDNA in predicting…
- Trial name
- DEFILE (NCT06476717)
- Testing
- Biopsy, Blood Biomarkers - cfDNA, Antirejection therapy
- Where
- Czechia
- Volunteers
- 143 people
- Sponsor
- Institute for Clinical and Experimental Medicine